{"id":296023,"date":"2026-03-27T00:00:00","date_gmt":"2026-03-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0059-2024-biopharma-asthma-current-treatment-treatment-algorithms-claims-data-analysis-adult\/"},"modified":"2026-03-31T10:23:13","modified_gmt":"2026-03-31T10:23:13","slug":"algoim0059-2026-biopharma-asthma-current-treatment-treatment-algorithms-claims-data-analysis-adult-asthma-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0059-2026-biopharma-asthma-current-treatment-treatment-algorithms-claims-data-analysis-adult-asthma-us\/","title":{"rendered":"Asthma &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Adult Asthma (US)"},"content":{"rendered":"<p>Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation (e.g., a <abbr title=\"short-acting beta2 agonist\">SABA<\/abbr> such as Teva\u2019s ProAir <abbr title=\"hydrofluoroalkane\">HFA<\/abbr>). Maintenance therapies are inhaled, oral, or biological drugs (e.g., a <abbr title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr title=\"inhaled corticosteroid\">ICS<\/abbr> such as GSK\u2019s Advair; an anti-<abbr title=\"interleukin\">IL<\/abbr>-5 agent such as AZ\u2019s Fasenra) that are used to prevent exacerbations by targeting the underlying disease pathophysiology. Although multiple well-established therapies are available for adult asthma, the market has seen the approval and launch of even more agents, including novel biologics (e.g., AZ\u2019s Tezspire) and generic versions of blockbuster inhaled drugs (e.g., albuterol sulfate, formoterol \/ budesonide). These launches have intensified the competition in this market.). These launches have added treatment options and intensified the competition in this market.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult asthma patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult asthma patients?<\/li>\n<li>How has Sanofi \/ Regeneron\u2019s Dupixent been integrated into the treatment algorithm, and what is its source of business?<\/li>\n<li>What percentage of adult asthma patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of adult asthma patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p>Markets covered: United States<\/p>\n<p>Key companies: GlaxoSmithKline, AstraZeneca, Teva, Genentech, Merck, Boehringer Ingelheim, Sanofi, Regeneron, Mylan, Cipla, Par, Perrigo, Prasco<\/p>\n<p>Key drugs: Advair, Symbicort, Breo, ProAir, Xolair, Dupixent, Nucala, Fasenra, Tezspire, Spiriva, Trelegy, Airsupra<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW165229715 BCX0 round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Solution enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-296023","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-therapy-areas-respiratory","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296023","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":4,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296023\/revisions"}],"predecessor-version":[{"id":577777,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296023\/revisions\/577777"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296023"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}